CN108653846A - Integral type blood plasma protein isolate A immuno absorbence devices - Google Patents
Integral type blood plasma protein isolate A immuno absorbence devices Download PDFInfo
- Publication number
- CN108653846A CN108653846A CN201810141315.6A CN201810141315A CN108653846A CN 108653846 A CN108653846 A CN 108653846A CN 201810141315 A CN201810141315 A CN 201810141315A CN 108653846 A CN108653846 A CN 108653846A
- Authority
- CN
- China
- Prior art keywords
- adsorbent
- chamber
- blood plasma
- adsorbent chamber
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/09—Body tissue
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses integral type blood plasma protein isolate A immuno absorbence devices, including shell, the blood entry port being connected on shell and with its inside, blood outlet and plasma outlet port, the inner cavity of shell to be equipped with disengagement chamber and adsorbent chamber；The inner cavity both ends of shell are equipped with sealing ring；Hollow-fiber film is equipped in disengagement chamber；The both ends of hollow-fiber film, which plug, to be fixed on sealing ring and is connected to blood entry port and blood outlet；Disengagement chamber is connected to adsorbent chamber by the first perforated film for only allowing blood plasma to penetrate；Microspheroidal Protein A immunoadsorption agent is equipped in adsorbent chamber.Beneficial effects of the present invention：By the way that disengagement chamber and adsorbent chamber is arranged, blood plasma separation progress synchronous with plasma adsorption may be implemented, avoid haemocyte and being in direct contact for adsorbent and improve biocompatibility；Regenerative therapy pattern or single adsorptions treatment mode can be independently selected according to conditions of patients；Consumables cost and treatment cost are reduced, adsorption effect is improved.
Description
Technical field
The present invention relates to medical instruments fields, in particular to a kind of integral type blood plasma protein isolate A immuno absorbence devices.
Background technology
Protein A immunoadsorption agent is a kind of filler of albumin A-carrier complexes, it is by the effect of chemical bond by albumin A
It is coupled on carrier matrix, the Fc section selective bindings of human immunoglobulin (mainly IgG) is inhaled using albumin A
It is attached.Protein A immunoadsorption therapy is a kind of new technology to grow up in recent decades, is difficult to for treating some conventional methods
The disease proved effective, such as systemic loupus erythematosus, myasthenia gravis, thrombocytopenic purpura autoimmune disease.
Plasma sorption therapy compares whole blood sorption therapy, small to injury of blood cell, small on human internal environment's influence, in blood
Field of purification is used widely.The basic principle of plasma sorption therapy is to guide to patient's body blood in vitro, first by blood plasma
It detaches with haemocyte, then is targetedly adsorbed and removed the morbid substance in blood plasma, to achieve the purpose that treat disease.
Current existing Protein A immunoadsorption treatment technology is that the blood that human body flows out first is pumped into blood plasma point through blood pump
From in device, blood plasma and haemocyte are separated by the sieving actoion of plasma separator, the blood plasma isolated then is passed through into blood
Pump is re-introduced into Protein A immunoadsorption column, utilizes the absorption of the Protein A immunoadsorption agent loaded in Protein A immunoadsorption column
The morbid substance in blood plasma is targetedly removed in effect.Wherein, what is filled in plasma separator is hollow-fiber film.This process
In concatenated equipment it is more, the operation difficulty of medical staff is larger, and the blood volume of extracorporal circulatory system is larger, the Medical treatment device of contact
The probability that the problems such as tool is more, this also makes haemolysis, blood coagulation while the body burden for increasing patient occurs increases, and increases
Security risk when treatment.In addition, a full set of plasma adsorption equipment cost is also relatively high.These above-mentioned problems lead to traditional blood plasma
Separator adds the treatment mode of Protein A immunoadsorption column to be difficult to be widely popularized at home.
The Chinese patent of 102631722 B of Publication No. CN discloses a kind of blood plasma separation suction carrying out blood purification
Adnexa may be implemented blood plasma separation and be carried out with while plasma adsorption, however the absorber is used to adsorb the absorption of morbid substance
Material is the adsorbent of threadiness, and there are theoretical defects and technical bottleneck.
First, fibrous adsorbent is on the one hand because its specific surface area is limited (the two difference decades of times), on the other hand because
Blood residence time (sorbing material and contacting blood time) shorter, the adsorption capacity ten of Fibriform adsorbents in its adsorption process
It is point limited, it cannot be satisfied medical standard (seeming an utterly inadequate amount particularly with the morbid substance in the human blood of complicated component).
Secondly, it is contemplated that safety, the volume of adsorbent can not be infinitely great in adsorption column product, such as professional standard
The blood chamber vol of adsorption column product is defined in YY0464 cannot be more than 200ml, and corresponding adsorbent volume is generally no greater than
400ml.Just because of this, the single adsorptions ability of Protein A immunoadsorption column is limited, in the market Protein A immunoadsorption column
Single antibody adsorption capacity is generally in 1.2~3g, and patient needs the antibody being purged to be limited to adsorb often up to tens grams
Ability, Protein A immunoadsorption column are clinically needed to carry out " absorption-regeneration-absorption " this circulation pattern, be promoted with reaching
Adsorption capacity and the purpose for meeting clinical treatment.And existing immuno absorbence device cannot achieve " absorption-regeneration-absorption " this
Circulation pattern.
In addition, it is necessary to, it is noted that inside the absorber of the patent disclosure of 102631722 B of Publication No. CN not
Subregion is carried out, causes the Fibriform adsorbents in shell to exist and adsorbs non-uniform situation, lead to its practical adsorption effect not
Ideal, adsorbent further increase patient's treatment cost using not exclusively.
Invention content
The purpose of the present invention is to provide a kind of integral type blood plasma protein isolate A immuno absorbence devices, with adsorption effect
It is good, consumables cost and the low feature for the treatment of cost.
To achieve the above object, the integral type blood plasma protein isolate A immuno absorbence devices designed by the present invention, including shell,
It is equipped on the shell and with its internal blood entry port being connected to, blood outlet and plasma outlet port, the inner cavity of the shell
Disengagement chamber and adsorbent chamber；The inner cavity both ends of the shell are equipped with sealing ring；Hollow-fiber film is equipped in the disengagement chamber；The sky
The both ends of core fiber film, which plug, to be fixed on the sealing ring and is connected to the blood entry port and blood outlet；The disengagement chamber and suction
Attached chamber is connected to by the first perforated film for only allowing blood plasma to penetrate；Microspheroidal Protein A immunoadsorption agent is equipped in the adsorbent chamber；
The adsorbent chamber is connected to the plasma outlet port.
Further, it is additionally provided in the adsorbent chamber and adsorbent chamber is divided into only permitting for the first adsorbent chamber and the second adsorbent chamber
Perhaps the second perforated film that blood plasma penetrates；First adsorbent chamber is connected to the disengagement chamber by first perforated film；It is described
It is divided into multiple independent cavitys equipped with multiple non-porous films in first adsorbent chamber, it is linear to be equipped with wave in each cavity
Adsorbent coherent film；The adsorbent coherent film is equipped with microspheroidal Protein A immunoadsorption agent；Second adsorbent chamber and institute
Plasma outlet port connection is stated, the microspheroidal Protein A immunoadsorption agent of free shape is equipped in second adsorbent chamber.Pass through multiple independences
Cavity effect so that adsorption space is divided, and avoids the adsorption effect of blood plasma by absorber placement position and angle
It influences, to ensure that effective absorption of blood plasma；Wavy adsorbent coherent film also improves adsorption area simultaneously, while
Supporting surface is provided for microspheroidal Protein A immunoadsorption agent, prevents microspheroidal Protein A immunoadsorption agent from tenesmus precipitation occurs and influences
Adsorption effect.
Preferably, adsorbent coherent film lower end is equipped with thickening part.By the setting of thickening part, adsorbent can be improved
Coherent film bears dynamics, prevents its rupture.
Still further, being additionally provided with the adding mouth being connected to the adsorbent chamber on the shell；The adding mouth passes through pipe
Road has been sequentially communicated pump and regenerated liquid.Pass through the effect of regenerated liquid so that absorber can realize " absorption-regeneration-absorption " this
One circulation pattern, to reach ideal therapeutic effect.
Preferably, the adding mouth being connected to second adsorbent chamber is additionally provided on the shell；The adding mouth passes through pipe
Road has been sequentially communicated pump and regenerated liquid.
Further, the volume of the microspheroidal Protein A immunoadsorption agent is 50~1000mL.
Preferably, the surface area of the hollow-fiber film is 0.1~2.0m2。
Further, the disengagement chamber is equipped with close to one end of the first perforated film for stopping that regenerated liquid enters in disengagement chamber
Barrier film, and barrier film is flexibly connected with shell.
Beneficial effects of the present invention：1, by the way that disengagement chamber and adsorbent chamber are arranged in the inner cavity of absorber, blood may be implemented
Slurry separation is synchronous with plasma adsorption to be carried out, and is avoided haemocyte and being in direct contact for adsorbent and is improved biocompatibility；
2, regenerative therapy pattern or single adsorptions treatment mode, wherein single adsorptions can independently be selected to treat mould according to conditions of patients
Formula can reduce the blood volume of extracorporal circulatory system；3, the treatment mode that traditional plasma separator adds Protein A immunoadsorption is compared,
Reduce consumables cost and treatment cost；4, existing Fibriform adsorbents are compared, the microspheroidal albumin A in the present invention is immune to be inhaled
Attached dose of adsorption effect is more preferable；5, by the way that adsorbent chamber is divided into the first adsorbent chamber and the second adsorbent chamber, realize that the classification to blood plasma is inhaled
Attached, adsorption effect is more preferable, and the utilization rate higher of Protein A immunoadsorption agent.
Description of the drawings
Fig. 1 is a kind of structural schematic diagram of embodiment of the integral type blood plasma protein isolate A immuno absorbence devices of the present invention.
Fig. 2 is the structural representation of the another embodiment of the integral type blood plasma protein isolate A immuno absorbence devices of the present invention
Figure.
Fig. 3 is the partial enlargement structural representation of Fig. 2.
Fig. 4 is the treatment schematic diagram of Fig. 2.
In figure, 1. shells；2. blood entry port；3. blood exports；4. plasma outlet port；5. disengagement chamber；6. adsorbent chamber；7. sealing
Circle；8. hollow-fiber film；9. the first perforated film；10. microspheroidal Protein A immunoadsorption agent；11. adding mouth；12. pump；13. regeneration
Liquid；14. the first adsorbent chamber；15. the second adsorbent chamber；16. the second perforated film；17. cavity；18. adsorbent coherent film；19. non-porous
Film；20. thickening part；21. barrier film.
Specific implementation mode
Below in conjunction with the drawings and specific embodiments, the present invention is described in further detail.
Embodiment 1
Integral type blood plasma protein isolate A immuno absorbence devices as shown in Figure 1, including shell 1, be set to shell 1 on and and its
Blood entry port 2, blood outlet 3 and the plasma outlet port 4 of inside connection, the inner cavity of shell 1 is equipped with disengagement chamber 5 and adsorbent chamber 6；Shell
1 inner cavity both ends are equipped with sealing ring 7；Hollow-fiber film 8 is equipped in disengagement chamber 5；The both ends of hollow-fiber film 8 plug be fixed on it is close
Seal 7 is simultaneously connected to blood entry port 2 and blood outlet 3；Disengagement chamber 5 and adsorbent chamber 6 by only allow that blood plasma in blood penetrates the
One perforated film 9 is connected to；Microspheroidal Protein A immunoadsorption agent 10 is equipped in adsorbent chamber 6；Adsorbent chamber 6 is connected to plasma outlet port 4.Shell
The adding mouth 11 being connected to adsorbent chamber 6 is additionally provided on body 1；Adding mouth 11 has been sequentially communicated pump 12 and regenerated liquid 13 by pipeline.
Disengagement chamber 5 is equipped with the barrier film 21 entered in disengagement chamber 5 for stopping regenerated liquid 13 close to one end of the first perforated film 9, and hinders
Gear film 21 is flexibly connected with shell 1；Pass through the effect of regenerated liquid 13 so that absorber can realize " absorption-regeneration-absorption " this
One circulation pattern, to reach ideal therapeutic effect.The volume of microspheroidal Protein A immunoadsorption agent 10 is preferably 50~
1000mL.The surface area of hollow-fiber film 8 is preferably 0.1~2.0m2。
Embodiment 2
Integral type blood plasma protein isolate A immuno absorbence devices as shown in figs. 2 to 4, the main spy of the present embodiment and embodiment 1
Levy identical, distinguishing characteristics is：It is additionally provided in adsorbent chamber 6 and adsorbent chamber 6 is divided into the first adsorbent chamber 14 and the second adsorbent chamber 15
Only allow blood in blood plasma penetrate the second perforated film 16, the second perforated film 16 allow regenerated liquid 13 penetrate；This specification
In " only allow blood in blood plasma transmission " or " only allowing blood plasma transmission " refer to the only blood plasma that can pass through in blood, and and it is not all
Only blood plasma can pass through in substance (blood and other)；First adsorbent chamber 14 is connected to disengagement chamber 5 by the first perforated film 9；First
It is divided into multiple independent cavitys 17 equipped with multiple non-porous films 19 in adsorbent chamber 14, it is linear to be equipped with wave in each cavity 17
Adsorbent coherent film 18；Adsorbent coherent film 18 is equipped with microspheroidal Protein A immunoadsorption agent 10；Second adsorbent chamber 15 and blood
4 connection of slurry outlet, the 15 interior microspheroidal Protein A immunoadsorption agent 10 for being equipped with free shape of the second adsorbent chamber.By multiple independent
The effect of cavity 17 so that adsorption space is divided, and avoids the adsorption effect of blood plasma by absorber placement position and angle
It influences, to ensure that effective absorption of blood plasma；For example, when the existing absorber vertical display for not carrying out subregion, inhale
Attached dose is generally in absorber lower end, and causes upper end blood plasma that cannot effectively adsorb, and causes plasma adsorption effect poor, and absorption is uneven
It is even, and influence therapeutic effect.Wavy adsorbent coherent film 18 also improves adsorption area, especially adsorbent and adheres to simultaneously
When 18 direction as shown in Figure 3 of film is arranged, blood plasma needs just enter the second adsorbent chamber 15 after repeatedly penetrating adsorbent coherent film 18,
So that adsorption area increases, adsorption effect is improved；Adsorbent coherent film 18 is also microspheroidal Protein A immunoadsorption agent 10 simultaneously
Supporting surface is provided, prevents microspheroidal Protein A immunoadsorption agent 10 from tenesmus precipitation occurs and influences adsorption effect.
18 lower end of adsorbent coherent film is equipped with thickening part 20.By the setting of thickening part 20, adsorbent attachment can be improved
Film 18 bears dynamics, prevents its rupture.The adding mouth 11 being connected to the second adsorbent chamber 15 is additionally provided on shell 1；Adding mouth 11
It is sequentially communicated pump 12 and regenerated liquid 13 by pipeline.
After completing primary absorption, plasma inlet can be closed first with hemostatic clamp, then the closing of barrier film 21 (for example is inserted into
In shell 1) so that disengagement chamber 5 is isolated with adsorbent chamber 6, then regenerated liquid 13 is pumped into the second adsorbent chamber 15 by pump 12, is utilized
Regenerated liquid 13 restores the micro- of shape that dissociate in the agent 10 of microspheroidal Protein A immunoadsorption and the second adsorbent chamber 15 in the first adsorbent chamber 14
The adsorption capacity of globular preteins A immunosorbent 10；Hemostatic clamp is opened again and opens plasma inlet, and barrier film 21 is opened into (ratio
The extraction such as out of shell 1) so that disengagement chamber 5 is connected to adsorbent chamber 6, is repeated the above process, until reaching therapeutic dose.It needs
Illustrate, the setting structure of barrier film 21 and uses the prior art with the connection relation of shell 1.
When treatment, moved along direction as shown by the arrows in Figure 4 after the output of patient's body blood, blood first passes through blood entry port
2 enter in the hollow-fiber film 8 in the disengagement chamber 5 of integral type blood plasma protein isolate A immuno absorbence devices, and the blood plasma in blood can
Through hollow-fiber film 8 to be separated from whole blood, the visible component in blood in hollow-fiber film 8 is exported from blood
3 outflows.And the blood plasma isolated first penetrate the first perforated film 9, into each independent cavity 17, and with the attachment in cavity 17
Microspheroidal Protein A immunoadsorption agent 10 on adsorbent coherent film 18 contacts, and the substance of curing the disease in blood plasma is by microspheroidal albumin A
Immunosorbent 10 is adsorbed, and blood plasma is purified.Be fully cleaned up or preliminary purification after blood plasma again by the second perforated film 16,
Into in the second adsorbent chamber 15, continue to contact with the microspheroidal Protein A immunoadsorption agent 10 in the second adsorbent chamber 15, blood plasma is into one
Step is purified, and the blood plasma not being fully cleaned up in the first adsorbent chamber 14 especially can be fully cleaned up here, last net
The blood plasma of change is discharged from plasma outlet port 4 and inputs patient again after converging with the visible component in the blood of 3 outflow of blood outlet
In vivo.
Claims (8)
1. a kind of integral type blood plasma protein isolate A immuno absorbence devices, including shell (1), be set on the shell (1) and in it
Blood entry port (2), blood outlet (3) and the plasma outlet port (4) of portion's connection；It is characterized in that, the inner cavity of the shell (1) is equipped with
Disengagement chamber (5) and adsorbent chamber (6)；The inner cavity both ends of the shell (1) are equipped with sealing ring (7)；Sky is equipped in the disengagement chamber (5)
Core fiber film (8)；The both ends of the hollow-fiber film (8), which plug, to be fixed on the sealing ring (7) and is connected to the blood entry port
(2) and blood exports (3)；The disengagement chamber (5) and adsorbent chamber (6) are connected by the first perforated film (9) for only allowing blood plasma to penetrate
It is logical；Microspheroidal Protein A immunoadsorption agent (10) is equipped in the adsorbent chamber (6)；The adsorbent chamber (6) and the plasma outlet port
(4) it is connected to.
2. integral type blood plasma protein isolate A immuno absorbence devices according to claim 1, which is characterized in that the adsorbent chamber
(6) be additionally provided in only allows blood plasma transmission by what adsorbent chamber (6) was divided into the first adsorbent chamber (14) and the second adsorbent chamber (15)
Second perforated film (16)；First adsorbent chamber (14) is connected to the disengagement chamber (5) by first perforated film (9)；Institute
It states in the first adsorbent chamber (14) and is divided into multiple independent cavitys (17) equipped with multiple non-porous films (19), each cavity
(17) the adsorbent coherent film (18) of wave threadiness is equipped in；The adsorbent coherent film (18) is exempted from equipped with microspheroidal albumin A
Epidemic disease adsorbent (10)；Second adsorbent chamber (15) is connected to the plasma outlet port (4), is equipped in second adsorbent chamber (15)
The microspheroidal Protein A immunoadsorption agent (10) of free shape.
3. integral type blood plasma protein isolate A immuno absorbence devices according to claim 2, which is characterized in that the adsorbent
Coherent film (18) lower end is equipped with thickening part (20).
4. integral type blood plasma protein isolate A immuno absorbence devices according to claim 1, which is characterized in that the shell (1)
On be additionally provided with the adding mouth (11) being connected to the adsorbent chamber (6)；The adding mouth (11) has been sequentially communicated pump by pipeline
(12) and regenerated liquid (13).
5. integral type blood plasma protein isolate A immuno absorbence devices according to claim 2, which is characterized in that the shell (1)
On be additionally provided with the adding mouth (11) being connected to second adsorbent chamber (15)；The adding mouth (11) has been sequentially communicated by pipeline
Pump (12) and regenerated liquid (13).
6. integral type blood plasma protein isolate A immuno absorbence devices according to claim 1 or 2, which is characterized in that the microballoon
The volume of shape Protein A immunoadsorption agent (10) is 50~1000mL.
7. integral type blood plasma protein isolate A immuno absorbence devices according to claim 1 or 2, which is characterized in that described hollow
The surface area of tunica fibrosa (8) is 0.1~2.0 ㎡.
8. integral type blood plasma protein isolate A immuno absorbence devices according to claim 4 or 5, which is characterized in that the separation
Chamber (5) is equipped with the barrier film entered in disengagement chamber (5) for stopping regenerated liquid (13) close to one end of the first perforated film (9)
(21), and barrier film (21) is flexibly connected with shell (1).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810141315.6A CN108653846A (en) | 2018-02-11 | 2018-02-11 | Integral type blood plasma protein isolate A immuno absorbence devices |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810141315.6A CN108653846A (en) | 2018-02-11 | 2018-02-11 | Integral type blood plasma protein isolate A immuno absorbence devices |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108653846A true CN108653846A (en) | 2018-10-16 |
Family
ID=63784141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810141315.6A Pending CN108653846A (en) | 2018-02-11 | 2018-02-11 | Integral type blood plasma protein isolate A immuno absorbence devices |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108653846A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1196688A (en) * | 1996-06-20 | 1998-10-21 | 巴克斯特国际有限公司 | Affinity membrane system and method of using same |
| WO2000012103A1 (en) * | 1998-08-31 | 2000-03-09 | Ambrus Julian L | Method for removal of hiv and other viruses from blood |
| US20020086276A1 (en) * | 2000-12-28 | 2002-07-04 | Srivastava Pramod K. | Immunotherapeutic methods for extracorporeal modulation of CD36 and its ligands |
| CN101815548A (en) * | 2007-09-11 | 2010-08-25 | Bhk株式会社 | Apparatus for purifying blood |
| CN102631722A (en) * | 2012-04-26 | 2012-08-15 | 珠海健帆生物科技股份有限公司 | Blood plasma separation adsorber capable of blood purification |
-
2018
- 2018-02-11 CN CN201810141315.6A patent/CN108653846A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1196688A (en) * | 1996-06-20 | 1998-10-21 | 巴克斯特国际有限公司 | Affinity membrane system and method of using same |
| WO2000012103A1 (en) * | 1998-08-31 | 2000-03-09 | Ambrus Julian L | Method for removal of hiv and other viruses from blood |
| US20020086276A1 (en) * | 2000-12-28 | 2002-07-04 | Srivastava Pramod K. | Immunotherapeutic methods for extracorporeal modulation of CD36 and its ligands |
| CN101815548A (en) * | 2007-09-11 | 2010-08-25 | Bhk株式会社 | Apparatus for purifying blood |
| CN102631722A (en) * | 2012-04-26 | 2012-08-15 | 珠海健帆生物科技股份有限公司 | Blood plasma separation adsorber capable of blood purification |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4614513A (en) | Method and apparatus for treatment to remove immunoreactive substances from blood | |
| US7326182B2 (en) | Method of using device for bio-affinity material for treatment of blood or plasma | |
| JP2004519281A (en) | System and method for versatile automated blood and fluid processing | |
| CN108348664A (en) | Fatty filter device | |
| CN102600521A (en) | Device and method for eliminating pathogens in blood | |
| EP2238079A2 (en) | Method and apparatus for increasing contaminant clearance rates during extracorporeal fluid treatment | |
| CN104815360A (en) | Circulating tumor cell filtration treatment instrument | |
| WO2004098680A1 (en) | Low density lipoprotein/fibrinogen adsorbent and adsorption apparatus capable of whole blood treatment | |
| CN109092263A (en) | A kind of low-density lipoprotein adsorbent and preparation method thereof | |
| WO2006012885A1 (en) | Filter system for treating liquids containing particles using membrane isolation and adsorption | |
| CN108042866A (en) | For treating the plasma filtering device of acute cerebral infarction and method | |
| CN108404239A (en) | Integral type blood plasma detaches myoglobins absorber | |
| CN108653846A (en) | Integral type blood plasma protein isolate A immuno absorbence devices | |
| CN105214158B (en) | Apparatus for purifying blood and blood purification system | |
| CN108969818A (en) | The low-density lipoprotein absorber of blood plasma separation and plasma adsorption can be carried out simultaneously | |
| CN108434542A (en) | Integral type blood plasma detaches blood perfusion device | |
| CN108465136A (en) | Integral type blood plasma detaches Endotoxin adsorption device | |
| CN209075645U (en) | Blood toxicity absorber | |
| CN108283738A (en) | Integral type blood plasma detaches DNA immunization absorber | |
| CN108653848A (en) | Integral type blood plasma detaches IgE immuno absorbence devices | |
| CN108578807A (en) | Integral type blood plasma isolating hepatitis c virus immuno absorbence device | |
| CN108607126A (en) | Integral type blood plasma detaches HBV Immunity absorber | |
| CN108653847A (en) | Integral type blood plasma detaches AIDS virus immuno absorbence device | |
| CN108283739A (en) | Integral type blood plasma detaches bilirubin adsorption device | |
| CN104906648B (en) | Blood perfusion device and extracorporeal circulation of blood pipe-line system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181016 |
|
| RJ01 | Rejection of invention patent application after publication |